Arbutus Biopharma Corp., et al. v. Moderna, Inc., et al. — Representing Moderna in a patent infringement litigation brought by Arbutus Biopharma and Genevant Sciences relating to Moderna’s COVID-19 vaccine.
Astellas Pharma Inc. et al v. Ascent Pharmaceuticals, Inc. et al. — Representing Astellas in a Hatch-Waxman litigation filed against Ascent Pharmaceuticals and MSN Laboratories related to Astellas’ Myrbetriq®, used to treat overactive bladder.
Boehringer Ingelheim Pharmaceuticals, Inc. et al. v. Mylan Pharmaceuticals, Inc. et al. — Representing Boehringer Ingelheim in a Hatch-Waxman litigation filed against Mylan related to Boehringer’s Tradjenta® (linagliptin) and Jentadueto® (linagliptin and metformin hydrochloride) tablets used to treat type II diabetes.
Boehringer Ingelheim Pharmaceuticals Inc., et al. v. [16 Defendants] — Representing Boehringer Ingelheim in Hatch-Waxman litigations filed against 16 defendants related to BI's Jardiance®, Glyxambi®, Synjardy®, and Synjardy® XR anti-diabetic tablets.
Bristol Myers Squibb Company Sprycel Patent Litigation — Represented BMS in multiple district court litigations against generic manufacturers regarding BMS’s Sprycel®—a cancer drug used to treat patients with chronic myelogenous leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. These cases settled on favorable terms for BMS and enabled BMS to maintain exclusivity years beyond the expiration of the compound patent in 2020.
Ferring Pharmaceuticals, Inc., et al. v. Finch Therapeutics Group, Inc., et al. — Represented Finch Therapeutics and The Regents of the University of Minnesota against Ferring Pharmaceuticals and Rebiotix in a patent infringement litigation involving microbiota therapy. The case resulted in a $25.8 million jury verdict and a finding of willful infringement.
Aardevo North America, LLC v. Agventure B.V. — Represented Agventure B.V. (Solynta) against Aardevo North American in an inter partes review proceeding related to Solynta’s ground-breaking hybrid seed potato breeding patent. Defeated institution.
